体外吸附剂血液治疗在毒性系统性炎症中的不良结局:可能机制探讨
本文为观点性文章,讨论体外血液净化(EBP)中吸附剂装置用于脓毒症及相关炎症性疾病时的不良结局。作者指出,此类治疗缺乏可证实的疗效,但通常被认为安全;然而自2020年末以来,四项使用吸附剂装置的临床研究报告患者死亡率显著增加,对研究设计与实施的批评未发现决定性缺陷,且均未考虑吸附治疗本身的毒性效应。作者结合生物医学工程与细胞因子分子动力学进展提出,炎症蛋白固定在固体支架或分子载体上可能稳定蛋白结构并保留或放大其功能,若该机制在EBP吸附治疗中 operative,吸附介质可能变得具有反应性,促进炎症活性并导致负面结局;作者呼吁对这些潜在有害机制开展研究。
要点
- 自2020年末以来,四项使用吸附剂装置的EBP临床研究报告患者死亡率显著增加,与吸附治疗相关。
- 对上述研究的批评未发现决定性缺陷,且均未考虑吸附治疗本身的潜在毒性效应。
- 作者提出,炎症蛋白固定在固体支架或分子载体上可能稳定蛋白结构并保留或放大蛋白功能。
- 若上述机制在EBP吸附治疗中 operative,吸附介质可能变得具有反应性,促进炎症活性并导致负面结局。
- 作者认为,鉴于近期不同炎症条件下吸附治疗出现伤害的报告,应警惕并研究这些装置中可能有害的机制。
适用人群与场景
- 脓毒症及相关疾病、接受体外血液净化(EBP)吸附剂治疗以减轻毒性系统性炎症的患者。
红旗征与不能漏的情况
- 使用吸附剂装置进行EBP治疗炎症性疾病时,需警惕吸附治疗本身可能带来的有害效应;四项临床研究报告吸附剂治疗与患者死亡率显著增加相关。
研究设计与关键结果
- 本文为观点性文章,非系统研究;作者汇总指出,自2020年末以来四项使用吸附剂装置的EBP临床研究报告患者死亡率显著增加,且对研究设计与实施的批评未发现决定性缺陷。
- 作者基于过去二十年生物医学工程与细胞因子分子动力学进展提出,炎症蛋白固定在固体支架或分子载体上可能稳定蛋白结构并保留或放大蛋白功能。
- 作者指出,尚不清楚这些机制是否在EBP吸附治疗中 operative;若 operative,吸附介质可能变得具有反应性,促进炎症活性并导致负面结局。
证据类型、等级与局限
- 证据类型:观点性文章(perspective);本文未提供系统评价或原始研究数据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,鉴于近期不同炎症条件下吸附治疗出现伤害的报告,应警惕并研究这些装置中可能有害的机制。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Extracorporeal blood purification (EBP) treatments may be used in patients with sepsis and related conditions to mitigate toxic systemic inflammation, prevent or reverse vital organ injury, and improve outcome. These treatments lack demonstrable efficacy, but are generally considered safe. However, since late 2020, four clinical studies of EBP treatment using adsorbent devices in inflammatory disease reported significantly increased patient mortality associated with the adsorbent treatments. Criticisms of study design and execution were published, but revealed no decisive flaws. None of these critiques considered possible toxic effects of the adsorbent treatments per se.
PERSPECTIVE AND CONCLUSION: In adsorbent EBP treatment of systemic inflammatory disease the adsorbent media are deployed in patient blood or plasma flow for the purpose of broad spectrum, non-specific adsorptive removal of inflammatory mediators. Adsorption and sequestration of inflammatory mediators by adsorbent media is intended to reduce mediator concentrations in circulating blood and neutralize their activity. However, in the past two decades developments in both biomedical engineering and the science of cytokine molecular dynamics suggest that immobilization of inflammatory proteins on solid scaffolds or molecular carriers may stabilize protein structure and preserve or amplify protein function. It is unknown if these mechanisms are operative in EBP adsorbent treatments. If these mechanisms are operative, then the adsorbent medium could become reactive, promoting inflammatory activity which could result in negative outcomes. Considering the recent reports of harm with adsorbent treatments in diverse inflammatory conditions, caution urges investigation of these potentially harmful mechanisms in these devices. Candidate mechanisms for possible inquiry are discussed.
参考来源
- Matson J, Lange P, Honore PM, et al. Adverse outcomes with extracorporeal adsorbent blood treatments in toxic systemic inflammation: a perspective on possible mechanisms. Ann Intensive Care. 2022. PMID: 36370238. doi:10.1186/s13613-022-01078-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。